3-(3-carboxy-4-hydroxyphenyl)alanine | 4303-95-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(3-carboxy-4-hydroxyphenyl)alanine
• 英文别名: 3-(3-carboxy-4-hydroxyphenyl)-L-alanine；3-<4-Hydroxy-3-carboxy-phenyl>-L-alanin；3-(3-Carboxy-4-hydroxyphenyl)alanin；DL-3-Carboxytyrosine；5-[(2S)-2-amino-2-carboxyethyl]-2-hydroxybenzoic acid
• CAS: 4303-95-1
• 化学式: C₁₀H₁₁NO₅
• 分子量: 225.201
• InChiKey: AZXBADPWXOWMKQ-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  9-芴甲基-N-琥珀酰亚胺基碳酸酯 、 3-(3-carboxy-4-hydroxyphenyl)alanine 在 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 5-[(S)-2-Carboxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-2-hydroxy-benzoic acid
  参考文献：
  名称：

  Tyrosine analogues as alternative substrates for protein tyrosine kinase Csk: Insights into substrate selectivity and catalytic mechanism

  摘要：

  Protein tyrosine kinases are critical enzymes in cell signal transduction but relatively little is known about the molecular recognition of the tyrosine substrate by these enzymes. Details of tyrosine substrate specificity within the context of a short peptide were investigated for protein tyrosine kinase Csk. It was found that aryl ring functional group substitutions the size of methyl group or smaller were generally well tolerated by the protein tyrosine kinase Csk whereas larger groups caused a decline in substrate efficiency. Extension of the phenol from the peptide backbone by a single methylene was acceptable for phosphorylation whereas removal of a methylene nearly abolished reactivity. Only the L-tyrosine derivative was processed. A negative charge ortho to the phenol hydroxyl was incompatible with substrate reactivity, consistent with previous pH rate profiles which indicated the importance of the neutral phenol. Overall, these studies confirmed the interpretation of a previous linear free energy relationship analysis which suggested that the enzyme followed a dissociative transition state mechanism. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00053-5
• 作为产物：
  描述：

  Boc-L-酪氨酸 在 sodium chlorite 、 sodium dihydrogenphosphate 、 水 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 7.0h， 生成 3-(3-carboxy-4-hydroxyphenyl)alanine
  参考文献：
  名称：

  一种(S)-3-Carboxytyrosine的制备方法

  摘要：

  本发明公开一种(S)‑3‑Carboxytyrosine的制备方法，该方法从商业可得的酪氨酸出发，经过Reimer&Tiemann反应在邻酚羟基上进行甲酰化，再Pinnick氧化反应成酸，最后脱Boc制备得到最终产物(S)‑3‑Carboxytyrosine，利用氨基酸等电点可重结晶得到HPLC纯度80%以上的终产物。本发明首次实现了(S)‑3‑Carboxytyrosine的全合成，提供了一种(S)‑3‑Carboxytyrosine的克级的简易制备路线，合成路线短，工艺简单。

  公开号：

  CN117843513A

文献信息

• C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020042376A1

  公开（公告）日：2002-04-11

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及在治疗患有炎症性、自身免疫和神经退行性疾病的患者中使用这些组合物，用于预防缺血性损伤，并用于保存即将进行移植手术的器官。
• Amino acid derived prodrugs of propofol, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20050004381A1

  公开（公告）日：2005-01-06

  The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

  本发明提供了丙泊酚前药、制备丙泊酚前药的方法、丙泊酚前药的药物组合物以及使用丙泊酚前药和药物组合物治疗或预防偏头痛疼痛、化疗后或手术后恶心和呕吐等疾病或失调的方法。
• Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
  申请人：Idun Pharmaceuticals, Inc.

  公开号：US20020123522A1

  公开（公告）日：2002-09-05

  The present invention provides methods for expanding and increasing survival of hematopoietic cell populations, for prolonging viability of an organ for transplantation, and enhancing bioproduction, using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors. Exemplary compounds useful in the methods of the invention are provided herein.

  本发明提供了一种使用白细胞介素-1β转化酶（ICE）/CED-3家族抑制剂来扩展和增加造血细胞群体的存活、延长移植器官的存活能力和增强生物生产的方法。本发明中提供了可用于该方法中的典型化合物。
• TREATMENT OF INFECTIOUS DISEASE USING INTERLEUKIN-1BETA-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
  申请人：Idun Pharmaceuticals, Inc.

  公开号：US20020128306A1

  公开（公告）日：2002-09-12

  The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.

  本发明提供了一种通过抑制白细胞介素-1β转化酶（ICE）/CED-3家族蛋白酶的活性来治疗传染病、抑制相关炎症或缓解症状的方法和组合物。还提供了用于这些目的的组合物。本发明方法中有用的示例化合物在此提供。
• Methods, compositions and kits for preserving antigenicity
  申请人：——

  公开号：US20030039661A1

  公开（公告）日：2003-02-27

  The present invention relates generally to programmed cell death and specifically to methods, compositions, and kits for preserving or enhancing antigenicity of markers associated with disease by utilizing inhibitors of apoptosis including interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors.

  本发明一般涉及程序性细胞死亡，具体涉及利用凋亡抑制剂包括白细胞介素-1β转化酶（ICE）/CED-3家族抑制剂来保存或增强与疾病相关标记的抗原性的方法、组合物和试剂盒。